Skip to main content
SpringerLink
Log in

Risedronate: a bisphosphonate with improved gastrointestinal tolerability

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gatti D, Adami S. New bisphosphonates in the treatment of bone diseases. Drugs Aging 1999 Oct; 15: 285–96

    Article  PubMed  CAS  Google Scholar 

  2. Dunn CJ, Goa KL. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease. Drugs 2001; 61(5): 685–712

    Article  PubMed  CAS  Google Scholar 

  3. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999 Oct 13; 282: 1344–52

    Article  PubMed  CAS  Google Scholar 

  4. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000; 11: 83–91

    Article  CAS  Google Scholar 

  5. Hooper M, Hanley DA, Eastell R, et al. Sustained effect of risedronate in the prevention of the first vertebral fracture in women [abstract]. J Bone Miner Res 2000 Sep; 15 Suppl. 1: S428

    Google Scholar 

  6. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 349(9050): 1535–41

    Article  Google Scholar 

  7. Ebeling P, Roberts A, D’Emden M, et al. Risedronate prevents bone loss in early postmenopausal women [abstract no. SA377]. J Bone Miner Res 1999; 14 Suppl. 1: S403

    Google Scholar 

  8. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344(5): 333–40

    Article  PubMed  CAS  Google Scholar 

  9. Harris ST, Wasnich R, Ettinger M, et al. The effects of risedronate plus estrogen compared with estrogen alone in postmenopausal women [abstract]. J Bone Miner Res 1999 Sep; 14 Suppl.: 29

    Article  Google Scholar 

  10. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999 Nov; 42: 2309–18

    Article  PubMed  CAS  Google Scholar 

  11. Reid DM, Hughes RA, Lann RFJM, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000; 15(6): 1006–13

    Article  PubMed  CAS  Google Scholar 

  12. Hosking DJ, Eusebio RA, Chines AA. Paget’s disease of bone: reduction of disease activity with oral risedronate. Bone 1998; 22(1): 51–5

    Article  PubMed  CAS  Google Scholar 

  13. Siris ES, Chines, Altman RD, et al. Risedronate in the treatment of Paget’s disease of bone: an open label, multicenter study. J Bone Miner Res 1998 Jun; 13: 1032–8

    Article  PubMed  CAS  Google Scholar 

  14. Miller PD, Brown JP, Siris ES, et al. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’ disease of bone. Am J Med 1999 May; 106: 513–20

    Article  PubMed  CAS  Google Scholar 

  15. Aventis Pharmaceuticals Inc. Actonel (risedronate sodium tables) prescribing information. Kansas City (MO): Aventis Pharmaceuticals Inc, Apr 2000

    Google Scholar 

  16. Fogelman I, Moreland L, Woodson G, et al. Gastrointestinal side effects and endoscopic findings similar between risedronate and placebo-treated patients. Osteoporosis Int 2000; 11 Suppl 2: S179

    Google Scholar 

  17. Hosking D, Bockman R, Glowinkski J, et al. Similar gastrointestinal side effects and endoscopie findings between risedronate and placebo-treated patients. J Bone Miner Res 2000 Sep; 15 Suppl. 1: S428

    Google Scholar 

  18. Lanza FL, Hunt RH, Thomson ABR, et al. Endoscopie comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119: 631–8

    Article  PubMed  CAS  Google Scholar 

  19. Lanza F, Schwartz H, Sahba B, et al. An endoscopie comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000; 95: 3112–7

    Article  PubMed  CAS  Google Scholar 

  20. Adachi JD, Adami S, Miller PD, et al. Risedronate is well-tolerated in alendronate-intolerant postmenopausal women [abstract]. J Bone Miner Res 2000 Sep; 15 Suppl. 1: S429

    Google Scholar 

  21. British National Formulary. No. 41. London: The Pharmaceutical Press, 2001 Mar

  22. Adachi JD, Papaioannou A. Corticosteroid-induced osteoporosis: detection and management. Drug Saf 2001; 24(8): 607–24

    Article  PubMed  CAS  Google Scholar 

  23. Castelo-Branco, C. Management of osteoporosis: an overview. Drugs Aging 1998; 12 Suppl. 1: 25–32

    Article  PubMed  Google Scholar 

  24. Rackoff PJ, Rosen CJ. Pathogenesis and treatment of glucocorticoid-induced osteoporosis. Drugs Aging 1998 Jun; 12(6): 477–84

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Risedronate: a bisphosphonate with improved gastrointestinal tolerability. Drugs Ther. Perspect 17, 1–4 (2001). https://doi.org/10.2165/00042310-200117220-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117220-00001

Keywords

Search

Navigation